Faisal Humayun

Faisal Humayun

InvestorPlace Contributor

Expertise: Oil and Gas, Electric Vehicles, Emerging Growth Stories

Education: Bachelor of Science, MBA with Specialization in Finance

About Faisal:
Faisal Humayun is an MBA in Finance and a senior research analyst with 14 years of experience in the field of equity, credit, industry and economic research. While working as a senior analyst, he has been involved in financial modelling, valuation analysis and credit rating.

As a freelancer, Faisal has authored over 1,500 articles for various publications that include Seeking Alpha, GuruFocus, Motley Fool, Trading Ideas and Red Pulse. His primary focus is on fundamental analysis using the top-down as well as bottom-up approach to stock selection.

Faisal is also an active trader with focus on price action trading strategy. A combination of long-term investing and short-term trading has produced decent results in a decade long exposure to equity markets. However, his favorite asset class is precious metals.

Additionally, Faisal has been researching cryptocurrencies in the last few quarters. His focus is not on the blue-chip coins, but on emerging altcoins that can be value creators.

You can learn more about Faisal at his profile on LinkedIn.

Recent Articles

7 of the Best Stocks to Buy for Their Free Cash Flow

By Faisal Humayun, InvestorPlace Contributor

These stocks to buy have a stable business outlook and robust free cash flows. They can create value through dividends and repurchases.

Good Time to Book Profits in Lucid Stock

By Faisal Humayun, InvestorPlace Contributor

LCID stock has surged by 100% in the recent past. A correction seems imminent. Long-term outlook for LCID stock remains positive.

4 Underperforming Stocks to Buy for a Reversal Rally

By Faisal Humayun, InvestorPlace Contributor

Underperforming stocks that look poised for a strong reversal in the coming quarters. Fundamentally strong underperforming stocks.

Sundial Stock Seems Way Overdue for a Big Rally Soon

By Faisal Humayun, InvestorPlace Contributor

SNDL stock looks poised for upside with ample cash buffer for investments. Growth of own brand and acquisitions to drive cash flow upside.

Avoid Ocugen — The Vaccine Is Too Little, Too Late

By Faisal Humayun, InvestorPlace Contributor

With high percentage of vaccination in U.S. and Canada, Ocugen has a limited addressable market. With the company still waiting for official FDA approval for the Covaxin, it's advisable for investors to stay away.

Load More